These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28699529)

  • 1. Targeting Protein Kinases for the Treatment of Glioblastoma Multiforme: Linking Basic Studies to Clinical Applications.
    Zhou A
    Curr Pharm Des; 2017 Nov; 23(29):4290-4302. PubMed ID: 28699529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting multiple kinases in glioblastoma multiforme.
    Sathornsumetee S; Reardon DA
    Expert Opin Investig Drugs; 2009 Mar; 18(3):277-92. PubMed ID: 19243279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The therapeutic potential of Aurora kinases targeting in glioblastoma: from preclinical research to translational oncology.
    de Almeida Magalhães T; de Sousa GR; Alencastro Veiga Cruzeiro G; Tone LG; Valera ET; Borges KS
    J Mol Med (Berl); 2020 Apr; 98(4):495-512. PubMed ID: 32219470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic strategies to target multiple kinases in glioblastoma.
    Sathornsumetee S
    Anticancer Agents Med Chem; 2011 Oct; 11(8):700-11. PubMed ID: 21707500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein Kinases as Tumor Biomarkers and Therapeutic Targets.
    Quan C; Xiao J; Liu L; Duan Q; Yuan P; Zhu F
    Curr Pharm Des; 2017 Nov; 23(29):4209-4225. PubMed ID: 28730960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme.
    Panner A; Parsa AT; Pieper RO
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1313-22. PubMed ID: 17020463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.
    Mao H; Lebrun DG; Yang J; Zhu VF; Li M
    Cancer Invest; 2012 Jan; 30(1):48-56. PubMed ID: 22236189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors.
    Yuan J; Zhang F; Hallahan D; Zhang Z; He L; Wu LG; You M; Yang Q
    J Exp Clin Cancer Res; 2018 Aug; 37(1):181. PubMed ID: 30071868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Kinase Signaling in Resistance to Bevacizumab Therapy for Glioblastoma Multiforme.
    Ramezani S; Vousooghi N; Joghataei MT; Chabok SY
    Cancer Biother Radiopharm; 2019 Aug; 34(6):345-354. PubMed ID: 31411929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eph receptors as therapeutic targets in glioblastoma.
    Day BW; Stringer BW; Boyd AW
    Br J Cancer; 2014 Sep; 111(7):1255-61. PubMed ID: 25144626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deregulated signalling networks in human brain tumours.
    Grzmil M; Hemmings BA
    Biochim Biophys Acta; 2010 Mar; 1804(3):476-83. PubMed ID: 19879382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving strategies: future treatment of glioblastoma.
    Chamberlain M
    Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
    Raizer JJ
    J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents.
    Minniti G; Muni R; Lanzetta G; Marchetti P; Enrici RM
    Anticancer Res; 2009 Dec; 29(12):5171-84. PubMed ID: 20044633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review on potential heterocycles for the treatment of glioblastoma targeting receptor tyrosine kinases.
    Bhusare N; Kumar M
    Oncol Res; 2024; 32(5):849-875. PubMed ID: 38686058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
    Ströbele S; Schneider M; Schneele L; Siegelin MD; Nonnenmacher L; Zhou S; Karpel-Massler G; Westhoff MA; Halatsch ME; Debatin KM
    PLoS One; 2015; 10(6):e0131670. PubMed ID: 26121251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaplastic Lymphoma Kinase in Glioblastoma: Detection/Diagnostic Methods and Therapeutic Options.
    Kalamatianos T; Denekou D; Stranjalis G; Papadimitriou E
    Recent Pat Anticancer Drug Discov; 2018; 13(2):209-223. PubMed ID: 29336268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular pathways and potential therapeutic targets in glioblastoma multiforme.
    Wardak Z; Choe KS
    Expert Rev Anticancer Ther; 2013 Nov; 13(11):1307-18. PubMed ID: 24168050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.